PARP inhibitors
MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients
The bioinformatics startup will work with Macrogen Europe to develop an AI-based tool for analyzing WGS data to identify patients who should receive PARP inhibitors.
Burning Rock, Impact Therapeutics Ink Testing Deal for ATR Inhibitor
The company will test samples to support Impact's Phase I/II trial combining the investigational drug IMP9064 with the PARP inhibitor senaparib.
Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development
The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Prostate Cancer Genomics Study IDs PARP Inhibitors as Potentially Beneficial to Black Men
Some genes were more frequently mutated in prostate cancers from Black men, but the researchers said that social inequities also lead to poorer health outcomes.